CSIMarket
 
Insmed Inc  (NASDAQ: INSM)
Other Ticker:  
 
 
Price: $99.4600 $-0.82 -0.818%
Day's High: $101.408 Week Perf: 1.51 %
Day's Low: $ 98.46 30 Day Perf: 47.96 %
Volume (M): 2,269 52 Wk High: $ 102.00
Volume (M$): $ 225,685 52 Wk Avg: $73.64
Open: $101.15 52 Wk Low: $60.40



 Market Capitalization (Millions $) 17,988
 Shares Outstanding (Millions) 181
 Employees 400
 Revenues (TTM) (Millions $) 272
 Net Income (TTM) (Millions $) -1,013
 Cash Flow (TTM) (Millions $) -192
 Capital Exp. (TTM) (Millions $) 27

Insmed Inc
Insmed Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for patients with unmet medical needs. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed is focused on developing therapies for serious respiratory diseases and rare diseases that have limited treatment options. The company's lead product, ARIKAYCE, is the first and only FDA-approved therapy for patients with Mycobacterium avium complex (MAC) lung disease, a rare and chronic infection that can cause significant damage to the lungs.

The company's pipeline includes several other novel product candidates in various stages of development. INS1007 is being developed for the treatment of non-cystic fibrosis bronchiectasis, a chronic and debilitating respiratory disease. INS1009 is being developed for the treatment of rare pulmonary diseases, including pulmonary alveolar proteinosis and alpha-1 antitrypsin deficiency.

Insmed is also developing therapies for rare diseases outside of the respiratory space. The company's pipeline includes INS1001, a potential treatment for rare genetic disorders, including Pantothenate kinase-associated neurodegeneration (PKAN) and other pantothenate kinase-associated disorders.

The company has a strong commitment to research and development and invests heavily in this area. Insmed has a global team of scientists and researchers who are dedicated to discovering and developing new therapies for patients in need.

Insmed has experienced significant growth in recent years, with a market cap of over $5 billion as of early 202 The company has a strong financial position, with a cash and cash equivalents balance of $499 million as of September 30, 2020.

Overall, Insmed is a leading biopharmaceutical company focused on developing and commercializing innovative therapies for serious respiratory diseases and rare diseases. The company has a strong commitment to research and development and is well-positioned for continued growth and success in the biopharmaceutical industry.


   Company Address: 700 US Highway 202/206 Bridgewater 8807 NJ
   Company Phone Number: 977-9900   Stock Exchange / Ticker: NASDAQ INSM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMRN   -3.56%    
CORT        0.08% 
SRPT   -44.33%    
TEVA   -3.67%    
VRTX   -2.53%    
VTRS   -3.52%    
• View Complete Report
   



Insmed Inc

Insmed Inc. Reports Significant Revenue Decline in Fiscal Q2 2024, Sparking Concerns Among Investorsnnnn


Insmed Inc.: Analyzing Recent Financial Performance and Market Potential
As the financial landscape continues to evolve, Insmed Inc. (NASDAQ: INSM) has elicited both concern and optimism among investors. With the company?s financial results for the period ending June 30, 2024, now in the spotlight, it?s crucial to dissect the data while acknowledging the broader implications for its future in the biotech sector.


Financial Overview
Insmed reported a shortfall per share of $-1.94, compared to $-1.78 during the same period last year and significantly widening from $-1.06 in the previous quarter. This reduction in earnings per share has raised eyebrows, signaling potential underlying challenges facing the company.

Stocks on the Move

Insmed Inc A Promising Biotech Company Showing Strong Performance in the Market

Published Sun, Jun 30 2024 11:40 AM UTC

In recent news, Insmed Inc (INSM) has emerged as a potential frontrunner in the biotech sector, demonstrating a commendable market performance. Analyst Jason Zemansky of Bank of America Securities has reiterated a Buy rating on Insmed, highlighting its positive market potential. Additionally, Barclays raised its price target on the stock, further boosting investor confidence...

Stocks on the Move

Insmed Inc (INSM) A Booming Future for Profitability and Stock Performance as Trial Results and Analyst Ratings Buoy ...

Published Tue, Jun 25 2024 11:04 AM UTC

Insmed Inc (INSM): A Promising Outlook for Profitability and Stock PerformanceInsmed Inc (NASDAQ: INSM) is garnering attention in the pharmaceutical industry as it presents a promising outlook for profitability and stock performance. Recent events and developments suggest a positive trajectory for the company, signaling potential growth and success in the near future.On June...

Stock Offering

Pioneering Biopharmaceutical Company, Insmed Incorporated, Leaps Forward in Fight Against Rare Diseases

Published Thu, May 30 2024 12:00 PM UTC


The Successful Offering:
Insmed Incorporated announced the pricing of its underwritten public offering, involving an impressive 12,621,359 shares of its stock. The proceedings from this offering are expected to generate substantial funding needed to further its crucial research and development efforts. By acquiring these funds, the company can invest in the experime...

Insmed Inc

Insmed Inc. Boasts Impressive 22.269% Revenue Surge in Fiscal First Quarter of 2024



Insmed Inc, a major player in the pharmaceutical industry, recently released its financial results for the period between January and March 31, 2024. While the company showcased a commendable decrease in its loss per share compared to the previous year, and a growth in revenue, a closer look reveals concerning trends that reflect a bearish outlook for the company. This article will delve into Insmed Inc's financial performance, highlighting certain key aspects that raise doubts about its long-term profitability.
Decreased Loss per Share Not Fully Encouraging:
Insmed Inc managed to decrease its loss per share to $-1.06 during the current reporting period, compared to $-1.17 in the previous year. This improvement may seem positive on the surface, but a closer examination reveals only a marginal decline. Furthermore, it is important to note that the company's EPS improved only slightly, from $-1.11 in the preceding reporting period. This indicates that Insmed Inc is struggling to rein in its losses and generate sustainable profits.







Insmed Inc's Segments
US    90.21 % of total Revenue
Japan    30.99 % of total Revenue
Europe and rest of world    9.07 % of total Revenue
Reportable Segment    130.27 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com